Jan 13 2025

GLP-1s reduce weight, with investigational therapies potentially more effective

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without diabetes, a systematic review published in Annals of Internal Medicine showed.
The analysis found that trial participants who received retatrutide (Eli Lilly) — an investigational triple agonist that activates the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), and glucagon receptors — experienced the greatest weight loss reductions among the agents studied.
Notably, some of the treatments that were the most effective have not

Read More

Healio.com ENDOCRINOLOGY • Diabetes for Doctors • 0